Hagar Labouta is a Keenan Professor of Medical Discovery at Unity health Toronto and Assistant Professor at the University of Toronto, jointly appointed in the Leslie Dan Faculty of Pharmacy and the Institute of Biomedical Engineering. She received her Ph.D. in pharmaceutical nanotechnology from Saarland University (Germany) and completed several Postdocs at Helmholtz institute (Germany), and University of Calgary (Canada). Her team is using microfluidics to design nanoparticles for the aim of breaching biological barriers in applications related to Women’s Health. To ensure clinical translation of the novel therapies designed in her lab, her team develops humanized organ-on-a-chip models for preclinical evaluation of nanoparticles. Her lab is well-funded by national and international funds. Dr. Labouta has a strong publication record and is a co-inventor on an international patent for the development of nanosystems for intracellular targeting. She has also worked with the WHO on two health-related projects. She has won several awards and fellowships including Rising Women in Science from the Controlled Release Society (USA), Member of the Year Award from the Controlled Release Society (USA), Interstellar Award from New York Academy of Sciences (USA), Innovation and Career Development Award by the Biomedical Engineering Society (USA), Apotheker Jacob Prize (Germany) and curriculum award for the Nanoscience Minor Program (Canada).